Literature DB >> 25851222

Dynamic role of extracellular matrix metalloproteinases in heart failure.

S C Tyagi1.   

Abstract

In chronic congestive heart failure, an illness affecting more than 4 million Americans, there is extensive myocardial extracellular matrix (ECM) remodeling. Failing human ventricular myocardium contains activated matrix metalloproteinases (MMPs) which are involved in adverse ECM remodeling. Our studies support the concept that impaired ECM remodeling and MMP activation are, in part, responsible for the cardiac structural deformation during heart failure. There is no known program which has declared its aim the investigation of regulation of fibrosis in hypertrophy and disruption of ECM in cardiac dilatation and failure. The development of transgenic technology, and emerging techniques for in vivo gene transfer, suggest a strategy for improving cardiac function by overexpressing or down regulation of the ECM components such as MMPs, tissue inhibitor of metalloproteinases (TIMPs), transforming growth factor β1 (TGFβ), decorin, collagen, and integrins in heart failure.

Entities:  

Year:  1998        PMID: 25851222     DOI: 10.1016/s1054-8807(97)00121-x

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  3 in total

Review 1.  Mitochondrial pathways to cardiac recovery: TFAM.

Authors:  George H Kunkel; Pankaj Chaturvedi; Suresh C Tyagi
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

Review 2.  Matrix metalloproteinase in left ventricular remodeling and heart failure.

Authors:  Suresh Shastry; Melvin R Hayden; Pamela A Lucchesi; Suresh C Tyagi
Journal:  Curr Cardiol Rep       Date:  2003-05       Impact factor: 2.931

3.  Major surgical trauma induces proteolysis of insulin-like growth factor binding protein-3 in transgenic mice and is associated with a rapid increase in circulating levels of matrix metalloproteinase-9.

Authors:  A Belizon; I Kirman; E Balik; M Karten; S Jain; R L Whelan
Journal:  Surg Endosc       Date:  2006-12-13       Impact factor: 3.453

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.